N B Vakil

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Acid inhibition and infections outside the gastrointestinal tract
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Am J Gastroenterol 104:S17-20. 2009
  2. ncbi Review article: cost-effectiveness of different GERD management strategies
    N Vakil
    University of Wisconsin Medical School, Sinai Samaritan Medical Center, Milwaukee, WI 53233, USA
    Aliment Pharmacol Ther 16:79-82. 2002
  3. ncbi Patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease
    N Vakil
    Division of Gastroenterology, University of Wisconsin Medical School, Milwauke, WI 53233, USA
    Aliment Pharmacol Ther 16:1469-80. 2002
  4. ncbi Clinical effectiveness of laparoscopic fundoplication in a U.S. community
    Nimish Vakil
    Department of Medicine, Division of Gastroenterology, University of Wisconsin Medical School, Aurora Sinai Medical Center, Milwaukee, 53233, USA
    Am J Med 114:1-5. 2003
  5. ncbi Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis
    N Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Aliment Pharmacol Ther 17:21-3. 2003
  6. ncbi Pneumatic dilation in achalasia
    N Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Endoscopy 35:526-30. 2003
  7. ncbi An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured
    Nimish Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Gastrointest Endosc Clin N Am 13:69-73, viii. 2003
  8. ncbi Long-term strategies: a medico-economic perspective
    Nimish Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, Milwaukee 53233, USA
    Eur J Gastroenterol Hepatol 16:853-6. 2004
  9. ncbi Proton pump inhibitors for dyspepsia
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisc, USA
    Dig Dis 26:215-7. 2008
  10. ncbi Review article: gastro-oesophageal reflux disease and Helicobacter pylori infection
    N B Vakil
    University of Wisconsin Medical School, Milwaukee, Wisconsin 53233, USA
    Aliment Pharmacol Ther 16:47-51. 2002

Collaborators

Detail Information

Publications70

  1. ncbi Acid inhibition and infections outside the gastrointestinal tract
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Am J Gastroenterol 104:S17-20. 2009
    ....
  2. ncbi Review article: cost-effectiveness of different GERD management strategies
    N Vakil
    University of Wisconsin Medical School, Sinai Samaritan Medical Center, Milwaukee, WI 53233, USA
    Aliment Pharmacol Ther 16:79-82. 2002
    ..Long-term management strategies now focus on discontinuous therapy for some subgroups of patients. On-demand therapy is particularly attractive for patients who have no mucosal disease...
  3. ncbi Patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease
    N Vakil
    Division of Gastroenterology, University of Wisconsin Medical School, Milwauke, WI 53233, USA
    Aliment Pharmacol Ther 16:1469-80. 2002
    ....
  4. ncbi Clinical effectiveness of laparoscopic fundoplication in a U.S. community
    Nimish Vakil
    Department of Medicine, Division of Gastroenterology, University of Wisconsin Medical School, Aurora Sinai Medical Center, Milwaukee, 53233, USA
    Am J Med 114:1-5. 2003
    ..The aim of our study was to determine the outcome of laparoscopic fundoplication for reflux disease in a cohort of patients who underwent this procedure in routine clinical practice...
  5. ncbi Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis
    N Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Aliment Pharmacol Ther 17:21-3. 2003
    ..Proton pump inhibitors are the most effective agents for treating erosive oesophagitis, but their relative efficacies have not been well characterized in large clinical trials...
  6. ncbi Pneumatic dilation in achalasia
    N Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Endoscopy 35:526-30. 2003
  7. ncbi An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured
    Nimish Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Gastrointest Endosc Clin N Am 13:69-73, viii. 2003
    ..This article summarizes the needed studies and the standards against which these procedures should be measured...
  8. ncbi Long-term strategies: a medico-economic perspective
    Nimish Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, Milwaukee 53233, USA
    Eur J Gastroenterol Hepatol 16:853-6. 2004
    ..The long-term management of the disease requires consideration of treatment efficacy and cost and must meet the needs of patients, physicians and third-party payers...
  9. ncbi Proton pump inhibitors for dyspepsia
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisc, USA
    Dig Dis 26:215-7. 2008
    ..Cost-effectiveness studies suggest that in young patients acid suppression alone is more cost-effective than either endoscopy or testing and treatment for H. pylori in areas with a low prevalence of H. pylori...
  10. ncbi Review article: gastro-oesophageal reflux disease and Helicobacter pylori infection
    N B Vakil
    University of Wisconsin Medical School, Milwaukee, Wisconsin 53233, USA
    Aliment Pharmacol Ther 16:47-51. 2002
    ..pylori may increase the risk for developing GERD, and some experts have suggested that chronic H. pylori infection may be of benefit. This article reviews the data on H. pylori infection and GERD and its treatment...
  11. ncbi Treatment of H. pylori infection: the reality
    N Vakil
    University of Wisconsin Medical School, Milwaukee 53233, USA
    Yale J Biol Med 71:119-24. 1998
    ..As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice...
  12. ncbi The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
    N B Vakil
    University of Wisconsin Medical School, Milwaukee, WI, USA
    Aliment Pharmacol Ther 15:927-35. 2001
    ..In patients with erosive oesophagitis, esomeprazole has produced significantly greater healing rates and improved symptom resolution vs. omeprazole...
  13. ncbi Review article: the cost of diagnosing Helicobacter pylori infection
    N Vakil
    Division of Gastroenterology, Department of Medicine, University of Winsconsin Medical School, 945 North 12th Street, Milwaukee, WI 53233, USA
    Aliment Pharmacol Ther 15:10-5. 2001
    ..This is particularly true when the prevalence of H. pylori infection is less than 30% as is seen in many developed countries. When the prevalence of H. pylori infection is high (>60%), low-cost antibody tests are cost-effective...
  14. ncbi Evidence-based health care: making health policy and management decisions
    N B Vakil
    University of Wisconsin Medical School, Milwaukee, USA
    Manag Care 10:22-4. 2001
    ..Managed care organizations will need to play a greater role in the development, evaluation, and incorporation of clinical trials into their strategies...
  15. ncbi Treatment options for functional dyspepsia
    N Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Dig Dis 19:240-3. 2001
    ..The treatment of this condition is still controversial and no single therapy is uniformly effective. In this article we review currently available treatment trials for non-ulcer dyspepsia...
  16. ncbi Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection
    N Vakil
    University of Wisconsin Medical School, Milwaukee, Wisconsin 53233, USA
    Aliment Pharmacol Ther 14:45-51. 2000
    ..Some studies have suggested that a substantial number of patients remain symptomatic after eradication therapy. Other studies suggest that gastro-oesophageal reflux disease (GERD) may develop as a result of H. pylori eradication...
  17. ncbi Novel methods of using proton-pump inhibitors
    Nimish Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
    Gastroenterol Clin North Am 31:S85-8. 2002
    ..There are few data on nocturnal symptoms, and some studies suggest that tachyphylaxis may develop with H2RA therapy. More data are required on the clinical effectiveness of combination therapy administered long-term...
  18. ncbi Identification of a novel penicillin-binding protein from Helicobacter pylori
    P Krishnamurthy
    Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    J Bacteriol 181:5107-10. 1999
    ..Expression of PBP 4, but not PBP 1, 2, or 3, is significantly increased during mid- to late-log-phase growth...
  19. ncbi Increasing compliance with long-term therapy: avoiding complications and adverse events
    Nimish Vakil
    University of Wisconsin Medical School, Madison, Wisconsin, USA
    Rev Gastroenterol Disord 5:S12-7. 2005
    ..Similarly, long-term therapy administered continuously reduces complications such as stricture and may decrease the development of dysplasia in Barrett's esophagus...
  20. ncbi The frontiers of reflux disease
    Nimish Vakil
    University of Wisconsin Medical School, Madison, USA
    Dig Dis Sci 51:1887-95. 2006
    ....
  21. ncbi Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis
    Nimish Vakil
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53233, USA
    Gastroenterology 131:390-401; quiz 659-60. 2006
    ..The aim of this study was to determine the diagnostic accuracy of alarm features in predicting malignancy by performing a metaanalysis based on the published literature...
  22. ncbi Toward a simplified strategy for managing dyspepsia
    Nimish Vakil
    University of Wisconsin Medical School, Madison, USA
    Postgrad Med 117:13-6. 2005
  23. ncbi Helicobacter pylori treatment: a practical approach
    Nimish Vakil
    Am J Gastroenterol 101:497-9. 2006
    ..Eradication rates have been falling in trials and in clinical practice around the world. A practical approach to the treatment of patients with H. pylori infection and those who fail initial eradication therapy is discussed...
  24. ncbi Helicobacter pylori eradication: equivalence trials and the optimal duration of therapy
    Nimish Vakil
    Am J Gastroenterol 100:1702-3. 2005
    ..The design of these trials requires careful consideration of clinical, statistical, and regulatory concerns. We discuss the importance and key factors relevant to equivalence trials...
  25. ncbi Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community
    Ingela Wiklund
    Outcomes Research, AstraZeneca R and D, , Sweden
    Am J Gastroenterol 101:18-28. 2006
    ..This may represent an appropriate threshold for patient selection in trials of GERD therapy and for more detailed evaluation of patients consulting with reflux symptoms in clinical practice...
  26. ncbi Guidelines for the management of dyspepsia
    Nicholas J Talley
    Division of Gastroenterology and Hepatology, Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:2324-37. 2005
    ..pylori eradication fails. There are very limited data to support the use of low-dose tricyclic antidepressants or psychological treatments in functional dyspepsia...
  27. ncbi Sequential therapy for Helicobacter pylori: time to consider making the switch?
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison
    JAMA 300:1346-7. 2008
  28. ncbi A BALANCING VIEW: Endoscopy in dyspepsia: a tale of two cities
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Am J Gastroenterol 102:476-7. 2007
  29. ncbi Helicobacter pylori treatment: is sequential or quadruple therapy the answer?
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Rev Gastroenterol Disord 8:77-82. 2008
    ..Evidence shows that both quadruple therapy and sequential therapy are superior to triple therapy in patients with resistant strains of H. pylori. Studies that compare sequential and quadruple therapy are necessary and are awaited...
  30. ncbi Body mass index and gastroesophageal reflux disease: implications of the obesity epidemic
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Dig Dis Sci 53:2291-2. 2008
  31. ncbi Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin and Marquette University College of Health Sciences, Milwaukee, Wisconsin 53233, USA
    Am J Gastroenterol 103:1906-19. 2008
    ..Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD...
  32. ncbi Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice
    Nigel Flook
    Department of Family Medicine at the University of Alberta in Edmonton
    Can Fam Physician 54:701-5. 2008
    ..To apply the recently published Montreal definition of gastroesophageal reflux disease (GERD) in primary care...
  33. ncbi An international primary care survey of GERD terminology and guidelines
    Nimish Vakil
    Division of Gastroenterology, University of Wisconsin Medical School, Milwaukee, Wisc, USA
    Dig Dis 26:231-6. 2008
    ..Terminology used to describe upper gastrointestinal disorders differs by country and language. However, the extent of variation in physician understanding of GERD and associated conditions and symptoms is not known...
  34. ncbi A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease
    John Dent
    Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia
    Am J Gastroenterol 103:20-6. 2008
    ..This double-blind, randomized, multicenter study investigated the efficacy and safety of AZD0865 in the treatment of patients with nonerosive reflux disease (NERD)...
  35. ncbi Eradication therapy for Helicobacter pylori
    Nimish Vakil
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Gastroenterology 133:985-1001. 2007
    ..In this article, we discuss the epidemiology and cellular mechanisms that result in antimicrobial resistance, the results of current eradication therapies, and new approaches to the management of Helicobacter pylori infection...
  36. ncbi Can famotidine and omeprazole be combined on a once-daily basis?
    Lars Fandriks
    Department of Gastrosurgical Research, Sahlgrenska University Hospital, Gothenburg, Sweden
    Scand J Gastroenterol 42:689-94. 2007
    ..The objective of this study was to determine whether co-administration of a well-characterized H2-receptor antagonist, famotidine, can be combined with the proton-pump inhibitor omeprazole...
  37. ncbi Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial
    Dino Vaira
    University of Bologna, Bologna, Italy
    Ann Intern Med 146:556-63. 2007
    ..Antimicrobial resistance has decreased eradication rates for Helicobacter pylori infection worldwide...
  38. ncbi The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Rev Gastroenterol Disord 6:221-6. 2006
    ..Alternate therapies include use of non-NSAID analgesics; low-dose NSAIDs; and concurrent administration of cytoprotective agents with NSAIDs, acid inhibitors, proton pump inhibitors, and COX-2 agents...
  39. ncbi Dyspepsia and GERD: breaking the rules
    Nimish Vakil
    Am J Gastroenterol 100:1489-90. 2005
    ..Empirical PPI therapy is an attractive alternative to endoscopic investigation in young dyspeptic patients who are not infected with Helicobacter pylori...
  40. ncbi Primary and secondary treatment for Helicobacter pylori in the United States
    Nimish Vakil
    University of Wisconsin Medical School and Marquette University College of Health Sciences, Milwaukee, Wisconsin, USA
    Rev Gastroenterol Disord 5:67-72. 2005
    ..This article discusses the issues involved in H. pylori eradication, the mechanism of antibiotic delivery to the mucus layer of the stomach, and primary and secondary treatment strategies for H. pylori in the United States...
  41. ncbi Helicobacter pylori: factors affecting eradication and recurrence
    Nimish Vakil
    Am J Gastroenterol 100:2393-4. 2005
    ..g., clarithromycin. Increasing the doses of potent proton pump inhibitors has small effects on eradication rates but there may be differences between proton pump inhibitors that need further study...
  42. ncbi Non-invasive tests for the diagnosis of H. pylori infection
    Nimish Vakil
    University of Wisconsin Medical School, Milwaukee, Wisconsin, USA
    Rev Gastroenterol Disord 4:1-6. 2004
    ..The choice of an appropriate test depends on the pre-test probability of infection, the characteristics of the test being used, and the cost-effectiveness of the test. This article reviews available non-invasive tests...
  43. ncbi Epigastric pain in dyspepsia and reflux disease
    Nimish Vakil
    University of Wisconsin Medical School, Madison, Wisconsin, USA
    Rev Gastroenterol Disord 3:S16-21. 2003
    ..The large number of patients presenting with epigastric pain has led to the development of empirical strategies...
  44. ncbi Are there geographical and regional differences in Helicobacter pylori eradication?
    Nimish Vakil
    University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 N 12 Street, Room 4040, Milwaukee, WI 53233, USA
    Can J Gastroenterol 17:30B-32B. 2003
    ..Understanding the regional and geographical differences in H pylori eradication can help physicians select the optimal treatment regimen in different regions...
  45. ncbi Gastroesophageal reflux disease and Helicobacter pylori infection
    Nimish Vakil
    Section of Gastroenterology, Department of Medicine, University of Wisconsin Medical School, Milwaukee, WI, USA
    Rev Gastroenterol Disord 3:1-7. 2003
    ..This article reviews each of the issues in the debate separately and concludes that there is little evidence to suggest a major effect of H. pylori eradication on the outcome of gastroesophageal reflux disease...
  46. ncbi Low-dose aspirin: protection from the panacea
    Nalini Guda
    University of Wisconsin Medical School, Milwaukee, USA
    Am J Gastroenterol 97:3202-3. 2002
  47. ncbi Nonulcer dyspepsia
    Nimish Vakil
    Division of Gastroenterology, Department of Medicine, University of Wisconsin Medical School, Aurora Sinai Medical Center, Milwaukee, WI 53233, USA
    Curr Gastroenterol Rep 4:455-8. 2002
    ..They are promising but need further study. Data are limited on 5-HT(3) antagonists and hypnotherapy. New treatment approaches are necessary for this common and often chronic condition...
  48. ncbi Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy
    Cristino Canga
    University of Wisconsin Medical School, Milwaukee 53233, USA
    Am J Gastroenterol 97:600-3. 2002
    ....
  49. ncbi The stool antigen test for detection of Helicobacter pylori after eradication therapy
    Dino Vaira
    Department of Internal Medicine and Gastroenterology, S Orsola Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Ann Intern Med 136:280-7. 2002
    ..Current noninvasive tests to confirm the eradication of Helicobacter pylori must be performed 4 weeks or more after eradication therapy is completed...
  50. ncbi Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection
    Luigi Gatta
    Department of Internal Medicine and Gastroenterology, University of Bologna, S. Orsola Halpighi Hospital, Bologna, Italy
    Am J Gastroenterol 99:823-9. 2004
    ..CONCLUSIONS: False negative breath and stool tests are equally common in patients taking proton pump inhibitors. Antacids do not impair the sensitivity of the breath tests or the stool test...
  51. ncbi Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage?
    Nalini M Guda
    University of Wisconsin Medical School, Milwaukee, Wisconsin, USA
    Am J Gastroenterol 99:1233-7. 2004
    ..Since 2001, one intravenous proton pump inhibitor (pantoprazole) has been available in the United States. A drug shortage bulletin was issued for this agent in 2003...
  52. ncbi How to test for Helicobacter pylori in 2005
    Nimish Vakil
    University of Wisconsin Medical School, Milwaukee, WI, USA
    Cleve Clin J Med 72:S8-13; discussion S14-21. 2005
  53. ncbi The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis
    Paul Moayyedi
    Gastroenterology Division, McMaster University, Hamilton, Ontario, Canada
    Gastroenterology 127:1329-37. 2004
    ..We conducted a systematic review to evaluate whether PPI therapy had any effect in nonulcer dyspepsia and constructed a health economic model to assess the cost-effectiveness of this approach...
  54. ncbi Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States
    William M Duck
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 10:1088-94. 2004
    ..01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice...
  55. ncbi Treatment of gastroesophageal reflux disease: defining endpoints that are important to patients
    Nimish Vakil
    University of Wisconsin Medical School and Marquette University College of Health Sciences, Milwaukee, Wisconsin, USA
    Rev Gastroenterol Disord 4:S3-7. 2004
    ....
  56. ncbi Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors
    James M Scheiman
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Am J Gastroenterol 101:701-10. 2006
    ..002). Esomeprazole was well tolerated and associated with better symptom control than placebo. CONCLUSIONS: For at-risk patients, esomeprazole was effective in preventing ulcers in long-term users of NSAIDs, including COX-2 inhibitors...
  57. ncbi Peptic ulcer bleeding: clips, heat, and outcome
    A Quadri
    University of Wisconsin Medical School, Milwaukee, USA
    Am J Gastroenterol 97:200-1. 2002
  58. ncbi The benefit of negative tests in non-ulcer dyspepsia
    Amnon Sonnenberg
    Department of Veterans Affairs Medical Center, Albuquerque, New Mexico 87108, USA
    Med Decis Making 22:199-207. 2002
    ..The aim of the present study is to develop a mathematical model for quantifying the impact of diagnostic tests on a patient's health-related quality of life (HRQL)...
  59. ncbi Functional dyspepsia: the devil in the details
    Nimish Vakil
    Am J Med 116:781-2. 2004
  60. ncbi New pharmacological agents for the treatment of gastroesophageal reflux disease
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Rev Gastroenterol Disord 8:117-22. 2008
    ..These include agents that reduce TLESRs, serotonergic agents/ prokinetics, long-acting PPIs, mucosal protectants, and antigastrin agents. One or more of these agents may be the future of GERD therapy...
  61. ncbi Usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD)
    Craig W Hayden
    Southem Arizona VA Health Care System and University of Arizona Health Sciences Center, Department of Medicine, Tucson 85723, USA
    Dig Dis Sci 47:1-8. 2002
    ..Being female and having acid regurgitation daily were positively associated with alternative medicine usage for GERD...
  62. ncbi Clinical guidelines: the blind leading the deaf?
    Nimish Vakil
    Am J Gastroenterol 99:2136-7. 2004
    ..Measures to involve community practitioners in guideline development may enhance their uptake in the community...
  63. ncbi Endoscopy in GERD: Boondoggle, Diagnostic Test, or Risk Management Tool?
    Nimish Vakil
    Am J Gastroenterol 103:276-8. 2008
    ..The role of routine endoscopic examination in GERD is therefore questionable and needs better definition in carefully designed trials...
  64. ncbi Proton pump inhibitors and the time trends for esophageal dilation
    Nalini M Guda
    University of Wisconsin Medical School, Aurora Sinai Medical Center, Milwaukee, Wisconsin 53233, USA
    Am J Gastroenterol 99:797-800. 2004
    ..The widespread use of proton pump inhibitors has not, however, abolished the need for esophageal dilation...
  65. ncbi Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis
    John M Inadomi
    Veterans Affairs Ann Arbor Health Systems, 2215 Fuller Road, Ann Arbor, MI 48105, USA
    Ann Intern Med 138:176-86. 2003
    ..However, subsequent surveillance of patients with Barrett esophagus but no dysplasia, even at 5-year intervals, is an expensive practice...
  66. ncbi Advances in gastrointestinal pharmacotherapy
    David C Metz
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 3:1167-79. 2005
    ..Nevertheless, the success of new biologics such as anti-TNFalpha agents augurs well for effective future therapies...
  67. ncbi Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori
    Chiara Ricci
    Department of Internal Medicine and Gastroenterology, University of Bologna, University Hospital S. Orsola-Malpighi, Bologna, Italy
    Am J Gastroenterol 99:1910-5. 2004
    ..20 to 0.65. CONCLUSION: In an asymptomatic population, serum gastrin (total and G-17) and pepsinogens I-II (and their ratio) do not discriminate nonatrophic versus antrum-restricted/predominant atrophic gastritis...
  68. ncbi Can the clinical history distinguish between organic and functional dyspepsia?
    Paul Moayyedi
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    JAMA 295:1566-76. 2006
    ..Upper gastrointestinal symptoms occur in 40% of the population. An accurate diagnosis would help rationalize investigation and treatment...
  69. ncbi The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus
    Nimish Vakil
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53233, USA
    Am J Gastroenterol 101:1900-20; quiz 1943. 2006
    ..A global consensus definition for GERD may simplify disease management, allow collaborative research, and make studies more generalizable, assisting patients, physicians, and regulatory agencies...
  70. ncbi Unrecognized GERD symptoms are associated with excessive daytime sleepiness in patients undergoing sleep studies
    Nalini Guda
    Department of Gastroenterology, Aurora Sinai Medical Center, Milwaukee, Wisconsin 53233, USA
    Dig Dis Sci 52:2873-6. 2007
    ..Patients with GERD had significantly greater sleepiness. Further studies of the impact of GERD treatment in this population are necessary...